Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

被引：8
|
作者：
Schellens, J. H. M.
Shapiro, G.
Pavlick, A. C.
Tibes, R.
Leijen, S.
Tolaney, S. M.
Diaz-Padilla, I.
Ramanathan, R. K.
Demuth, T.
Viscusi, J.
Cheng, J. D.
Lam, R.
Xu, Y.
Oza, A. M.
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] NYU, Ctr Canc, New York, NY USA
[4] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr, Scottsdale, AZ USA
[5] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[6] Merck & Co Inc, N Wales, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3068
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I study of the combination of gemcitabine (G), vinorelbine (V) and cisplatin (P) in patients (pts) with solid tumors.
    Schrijvers, D
    Dyck, J
    Van den Brande, J
    Wilmes, P
    Korst, A
    Lardon, F
    Vermorken, J
    ANNALS OF ONCOLOGY, 2000, 11 : 140 - 140
  • [32] Phase I trial of chloroquine (CQ)/hydroxychloroquine (HCQ) in combination with carboplatin-gemcitabine (CG) in patients with advanced solid tumors.
    Karim, Nagla Fawzy Abdel
    Ahmad, Imran
    Gaber, Ola
    Eldessouki, Ihab
    Olowokure, Olugbenga Olanrele
    Farooq, Maria
    Morris, John Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors
    Amin, Manik
    Minton, Susan E.
    LoRusso, Patricia M.
    Krishnamurthi, Smitha S.
    Pickett, Cheryl A.
    Lunceford, Jared
    Hille, Darcy
    Mauro, David
    Stein, Mark N.
    Wang-Gillam, Andrea
    Trull, Lauren
    Lockhart, A. Craig
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (01) : 84 - 95
  • [34] A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors
    Manik Amin
    Susan E. Minton
    Patricia M. LoRusso
    Smitha S. Krishnamurthi
    Cheryl A. Pickett
    Jared Lunceford
    Darcy Hille
    David Mauro
    Mark N. Stein
    Andrea Wang-Gillam
    Lauren Trull
    A. Craig Lockhart
    Investigational New Drugs, 2016, 34 : 84 - 95
  • [35] A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors
    C. Massard
    P. A. Cassier
    A. Azaro
    B. Anderson
    E. Yuen
    D. Yu
    G. Oakley
    K. A. Benhadji
    S. Pant
    Cancer Chemotherapy and Pharmacology, 2022, 90 : 335 - 344
  • [36] A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors
    Massard, C.
    Cassier, P. A.
    Azaro, A.
    Anderson, B.
    Yuen, E.
    Yu, D.
    Oakley, G., III
    Benhadji, K. A.
    Pant, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 90 (04) : 335 - 344
  • [37] Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
    Kollmannsberger, Christian K.
    Sharma, Sunil
    Shapiro, Geoffrey
    Chi, Kim N.
    Christensen, James
    Tassell, Vanessa Roberts
    Chao, Richard C.
    Faltaos, Demiana
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.
    Rasco, Drew W.
    Li, Yufeng
    Tang, Yuefen
    Men, Lichuang
    Wang, Hengbang
    Ji, Jiao
    Liang, Zhiyan
    Sun, Joan
    Amaya, Alex
    Huang, Yingjie
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors
    Mackay, HJ
    Hoekstra, R
    Eskens, FALM
    Loos, WJ
    Crawford, D
    Voi, M
    Van Vreckem, A
    Evans, TRJ
    Verweij, J
    CLINICAL CANCER RESEARCH, 2004, 10 (08) : 2636 - 2644
  • [40] A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers
    Gonzalez-Ochoa, Eduardo
    Milosevic, Michael
    Corr, Bradley
    Abbruzzese, James L.
    Girda, Eugenia
    Miller, Rachel W.
    Croke, Jennifer
    Mackay, Helen
    Lee, Yeh Chen
    Bowering, Valerie
    Ramsahai, Janelle
    Wang, Lisa
    D'Souza, April
    Kunos, Charles A.
    Oza, Amit M.
    Lheureux, Stephanie
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (08) : 1208 - 1214
12345